Max Lataillade

2.0k citations
50 papers · 1.3k · h-index 19

Impact in

  • Virology top 0.5%
    • HIV Research and Treatment
  • Infectious Diseases top 1%
    • HIV/AIDS drug development and treatment
    • HIV/AIDS Research and Interventions

Papers in

  • Infectious Diseases 37
    • HIV/AIDS drug development and treatment 35
    • HIV/AIDS Research and Interventions 14
  • Virology 25
    • HIV Research and Treatment 25
Co-authors
Michael J. Kozal (9 shared papers)Jennifer Chiarella (6 shared papers)Mark Krystal (15 shared papers)George J. Hanna (13 shared papers)Rong Yang (6 shared papers)Jean‐Michel Molina (6 shared papers)Donnie McGrath (3 shared papers)Victoria Wirtz (3 shared papers)
Journals
Antimicrobial Agents and Chemotherapy (5 papers)PLoS ONE (4 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (4 papers)Antiviral Therapy (4 papers)Journal of the International AIDS Society (3 papers)
Partner nations
United StatesUnited KingdomGermany

In The Last Decade

Max Lataillade

48 papers receiving 1.3k citations

Peers

Max Lataillade
Comparison fields: 5 of 54
  • Virology 743
  • Infectious Diseases 1.0k
  • Emergency Medicine 89
  • Hepatology 76
  • Molecular Medicine 23
Replace Brian Woodfall with:
Brian Woodfall United States
Malathi Shivaprakash United States
Annemarie M. J. Wensing Netherlands
Caroline E. Ridgway United Kingdom
Cindy Vavro United States
Scott C. Brun United States
Scott Brun United States
Howard Mayer United States
Nancy Ruíz United States
Ben Van Baelen United States
Max Lataillade relative to Brian Woodfall United States Brian Woodfall's profile →
Citations per field
00.5×2×4×5.7×
Brian Woodfall · 1×
Citations per year

Countries citing papers authored by Max Lataillade

Since Specialization
Citations

This map shows the geographic impact of Max Lataillade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Lataillade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Lataillade more than expected).

Fields of papers citing papers by Max Lataillade

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Lataillade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Lataillade. The network helps show where Max Lataillade may publish in the future.

Co-authors

The 25 scholars most cited alongside Max Lataillade, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Max Lataillade Line = papers co-authored together Max Lataillade links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría, Ploenchan Chetchotisakd, Jorge Alberto Corral, Neal David, Graeme Moyle, Marco Mancini, Lisa Percival, Rong Yang, Victoria Wirtz, Max Lataillade, Judith Absalon, Donnie McGrath
2010183
2
Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance
Antiviral Therapy ·Max Lataillade, Jennifer Chiarella, Michael J. Kozal
2007125
3
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection
New England Journal of Medicine ·Michael D. Miller, Judith A. Aberg, Gilles Pialoux, Pedro Cahn, Melanie Thompson, Jean‐Michel Molina, Beatriz Grinsztejn, Ricardo Sobhie Diaz, Antonella Castagna, Princy Kumar, Gulam Latiff, Edwin DeJesus, Mark Gummel, Margaret Gartland, Amy Pierce, Peter Ackerman, Cyril Llamoso, Max Lataillade
2020103
4
Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study
PLoS ONE ·Max Lataillade, Jennifer Chiarella, Rong Yang, Steven Schnittman, Victoria Wirtz, Jonathan Uy, Daniel Seekins, Mark Krystal, Marco Mancini, Donnie McGrath, Birgitte B. Simen, Michael D. Miller, Michael J. Kozal
2010101
5
A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results
HIV Clinical Trials ·Michael J. Kozal, Sergio Lupo, Edwin DeJesus, Jean‐Michel Molina, Cheryl McDonald, François Raffi, Jorge Benetucci, Marco Mancini, Rong Yang, Victoria Wirtz, Lisa Percival, Jenny Zhang, Li Zhu, Dilek Arikan, Awny Farajallah, Bach‐Yen Nguyen, Randi Y. Leavitt, Donnie McGrath, Max Lataillade, (unknown)
201270
6
Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors
Antimicrobial Agents and Chemotherapy ·Zhufang Li, Nannan Zhou, Yongnian Sun, Neelanjana Ray, Max Lataillade, George J. Hanna, Mark Krystal
201363
7
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068
Journal of Antimicrobial Chemotherapy ·Nannan Zhou, Beata Nowicka-Sans, Brian McAuliffe, Neelanjana Ray, B. Eggers, Hua Fang, Fan Li, Matthew D. Healy, David R. Langley, Carey Hwang, Max Lataillade, George J. Hanna, Mark Krystal
201356
8
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
The Lancet HIV ·Jacob Lalezari, Gulam Latiff, Cynthia Brinson, Juan Echevarría, Sandra Treviño‐Pérez, Johannes R. Bogner, Melanie Thompson, Jan Fourie, Otto A Sussmann Pena, Fernando C Mendo Urbina, Marcelo Martins, Iulian Diaconescu, David Stock, Samit R. Joshi, George J. Hanna, Max Lataillade
201552
9
The Hunt for HIV-1 Integrase Inhibitors
AIDS Patient Care and STDs ·Max Lataillade, Michael J. Kozal
200644
10
Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Neelanjana Ray, Carey Hwang, Matthew D. Healy, Jeannette M. Whitcomb, Max Lataillade, Megan Wind‐Rotolo, Mark Krystal, George J. Hanna
201340
11
Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
JAIDS Journal of Acquired Immune Deficiency Syndromes ·Max Lataillade, Nannan Zhou, Samit R. Joshi, Sangil Lee, David Stock, George J. Hanna, Mark Krystal, (unknown)
201736
12
Concurrent Outbreak of Multidrug-Resistant and Susceptible Subclones of Acinetobacter baumannii Affecting Different Wards of a Single Hospital
Infection Control and Hospital Epidemiology ·Joel N. Maslow, Thomas Glaze, Pamela Adams, Max Lataillade
200532
13
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
PLoS ONE ·Javier O Morales-Ramirez, Johannes R. Bogner, Jean‐Michel Molina, Johan Lombaard, Ira B. Dicker, David Stock, Michelle DeGrosky, Margaret Gartland, Teodora Pene Dumitrescu, Sherene Min, Cyril Llamoso, Samit R. Joshi, Max Lataillade
201832
14
Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing
PLoS ONE ·Max Lataillade, Jennifer Chiarella, Rong Yang, Michelle DeGrosky, Jonathan Uy, Daniel Seekins, Birgitte B. Simen, Elizabeth St. John, Elizabeth Moreno, Michael J. Kozal
201231
15
Prevalence of Low-Level HIV-1 Variants with Reverse Transcriptase Mutation K65R and the Effect of Antiretroviral Drug Exposure on Variant Levels
Antiviral Therapy ·Michael J. Kozal, Jennifer Chiarella, Elizabeth P. St. John, Elizabeth Moreno, Birgitte B. Simen, Todd E. Arnold, Max Lataillade
201128
16
Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial
Antiviral Therapy ·(unknown), Melanie Thompson, Jacob Lalezari, Richard Kaplan, Yvett Pinedo, Otto A Sussmann Pena, Pedro Cahn, David Stock, Samit R. Joshi, George J. Hanna, Max Lataillade
201626
17
Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
Pharmacology Research & Perspectives ·Samit R. Joshi, Disala Fernando, Stephanie Igwe, Litza McKenzie, Anu Shilpa Krishnatry, Fiona Halliday, Joyce Zhan, Thomas Greene, Jianfeng Xu, Geraldine Ferron‐Brady, Max Lataillade, Sherene Min
202022
18
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529
Antimicrobial Agents and Chemotherapy ·Ishani Landry, Li Zhu, Malaz Abu Tarif, Matthew Hruska, Brian M. Sadler, Maria Pitsiu, Samit R. Joshi, George J. Hanna, Max Lataillade, David W. Boulton, Richard Bertz
201619
19
In VitroCross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations
Antimicrobial Agents and Chemotherapy ·Zhufang Li, Brian Terry, William Olds, Tricia Protack, Carol Deminie, Beatrice Minassian, Beata Nowicka-Sans, Yongnian Sun, Ira B. Dicker, Carey Hwang, Max Lataillade, George J. Hanna, Mark Krystal
201319
20
Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)
Clinical Infectious Diseases ·Carey Hwang, Dirk Schürmann, Christian Sobotha, Marta Boffito, Heather Sevinsky, Neelanjana Ray, Palanikumar Ravindran, Hong Xiao, Christian Keicher, Andreas Hüser, Mark Krystal, Ira B. Dicker, Dennis M. Grasela, Max Lataillade
201717

About Max Lataillade

Max Lataillade is a scholar working on Infectious Diseases, Virology, Epidemiology, Emergency Medicine and Molecular Biology, having authored 50 papers that have together received 1.3k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (35 papers), HIV Research and Treatment (25 papers), HIV/AIDS Research and Interventions (14 papers), HIV-related health complications and treatments (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers), Biochemical and Molecular Research (2 papers), Hepatitis C virus research (2 papers) and Viral-associated cancers and disorders (1 paper). The work is most often cited by research in Virology (743 citations), Infectious Diseases (1.0k citations), Emergency Medicine (89 citations), Hepatology (76 citations) and Molecular Medicine (23 citations). Max Lataillade has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Michael J. Kozal, Jennifer Chiarella, Mark Krystal, George J. Hanna, Rong Yang, Jean‐Michel Molina, Donnie McGrath, Victoria Wirtz, Samit R. Joshi and Neelanjana Ray. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, PLoS ONE, JAIDS Journal of Acquired Immune Deficiency Syndromes, Antiviral Therapy and Journal of the International AIDS Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian WoodfallBreakdown of academic impact, for papers by Malathi ShivaprakashBreakdown of academic impact, for papers by Annemarie M. J. WensingBreakdown of academic impact, for papers by Caroline E. RidgwayBreakdown of academic impact, for papers by Cindy VavroBreakdown of academic impact, for papers by Scott C. BrunBreakdown of academic impact, for papers by Scott BrunBreakdown of academic impact, for papers by Howard MayerBreakdown of academic impact, for papers by Nancy RuízBreakdown of academic impact, for papers by Ben Van Baelen